Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.

Ivan Pourmir Reza-Thierry ElaidiZineb MaaradjiHortense De Saint BasileMonivann UngMohammed IsmailiLaure FournierBastien RanceLaure GibaultRym Ben DhiabBenoit GazeauElizabeth Fabre

Published in: Cancers (2023)

PD after DCB is an independent factor of longer post-progression survival with specific patterns that prompt to contemplate loco-regional treatments. TGR is a promising tool to assess the residual benefit of immunotherapy and justify the continuation of immunotherapy in addition to radiotherapy or surgery.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
minimally invasive
early stage
radiation therapy
coronary artery bypass
locally advanced
radiation induced
squamous cell carcinoma
acute coronary syndrome
coronary artery disease
surgical site infection
rectal cancer